USA's BayBio calls for California leadership to support life sciences
Despite historic economic woes, the US state of California's life sciences industry's output was greater than ever before. The number of treatments, technologies and devices available to patients increased 35% in 2009 as compared to 2008.
In total, there are 1,754 marketed products available to patients, doctors and clinics worldwide that have California origins, according to data released today by BayBio during the launch of the flagship industry study BayBio: IMPACT 2010. Additionally, the report identifies 233 pending treatments, technologies and cures that represent more than $50 billion in investments for new jobs, facilities and equipment in the immediate future. However, without appropriate economic policies and support for education, the State of California will see very little of this development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze